Prognostic evaluation of P53 and BCL2 proteins in MYC/BCL2 double expression DLBCL

Pu Huang; Shu Chen; Xin Yang; Yuanyuan Lei; Xiaoying XU; Yanxue Liu; Yuhong Guo; Yi Pan; Xianhuo Wang; Huilai Zhang; Kai FU; Bin Meng

Return

Prognostic evaluation of P53 and BCL2 proteins in MYC/BCL2 double expression DLBCL

VernacularTitle: P53及BCL2蛋白在双表达弥漫大B细胞淋巴瘤中的预后判断价值
Author: Pu HUANG ^{1
,

2
,

3
,

4} ; Shu CHEN ^{1
,

2
,

3
,

4} ; Xin YANG ^{1
,

2
,

3
,

4} ; Yuanyuan LEI ^{1
,

2
,

3
,

4} ; Xiaoying XU ^{1
,

2
,

3
,

4} ; Yanxue LIU ^{1
,

2
,

3
,

4} ; Yuhong GUO ^{1
,

2
,

3
,

4} ; Yi PAN ^{1
,

2
,

3
,

4} ; Xianhuo WANG ^{1
,

2
,

3
,

5} ; Huilai ZHANG ^{1
,

2
,

3
,

5} ; Kai FU ⁶ ; Bin MENG ^{1
,

2
,

3
,

4}
Author Information

1. Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer
2. Key Laboratory of Cancer Prevention and Therapy, Tianjin
3. Tianjin’s Clinical Research Center of Cancer, Tianjin 300060, China
4. Department of Pathology, Tianjin Medical University Cancer Institute and Hospital Tianjin 300060, China
5. Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital Tianjin 300060, China
6. Department of Pathology and Microbiology, UNMC, Omaha, USA
Publication Type:Journal Article
Keywords: Diffuse large B-cell lymphoma; Double-expression lymphoma; BCL2; P53; Prognosis
From: Chinese Journal of Hematology 2019;40(7):589-593
CountryChina
Language:Chinese
Abstract: Objective:To investigate the strong expression (S+) of P53 and BCL2 proteins in MYC/BCL2 double-expression DLBCL (DEL) and whether they can be used for the prognostic evaluation and stratified diagnosis of DELs.
Methods:Tissue microarray were made by filed FFPE blocks of 174 DLBCL cases. The translocation of MYC, BCL2 and BCL6 genes were detected by FISH, and the proteins were detected by IHC. Data of clinicopathologic features and follow up of patients were collected and OS (overall survival) and PFS (progression free survival) were analyzed by statistics.
Results:Eight double-hit lymphomas (DHLs) were identified in all cases, and 45 DELs were selected from 166 remaining cases, which have no significant difference in OS and PFS compared with non-DEL cases (P=0.668 and P=0.790) . Of 42 DEL-cases with follow up data, 24 cases with P53+ or/and BCL2 (S+) are significantly shorter OS and PFS than others (P=0.003 and P=0.000) , in which the cases with P53+/BCL2 (S+) co-expression were the worst prognosis, and P53/BCL2 co-weaker positive DEL cases even have superior OS and PFS than those non-DELs. Although statistics showed that the cases of P53+ or/and BCL2 (S+) have a lower OS and PFS in total cases (P=0.063 and P=0.024) , it is not the case when the DEL-cases take out from total cases, that is the cases with P53+ or/and BCL2 (S+) are as similar OS and PFS as others in non-DEL group (P=0.590 and P=0.550) .
Conclusion:The strong expression of P53 and BCL2 proteins can be used as indicators of stratified diagnosis and poor prognosis of DEL.